Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 80%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Levosimendan vs enoximone

All‐cause short‐term mortality: 30 days · adults with cardiogenic shock

It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.5 [0.22, 1.14]
1 study · 32 participants
Very low

Epinephrine vs norepinephrine‐dobutamine

All‐cause short‐term mortality: 28 days · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.25 [0.41, 3.77]
1 study · 30 participants
Very low

Epinephrine vs norepinephrine

All‐cause short‐term mortality: 28 daysÂ · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 daysÂ compared with norepinephrine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.81 [0.89, 3.68]
1 study · 57 participants
Very low

Levosimendan vs dobutamine

All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.6 [0.36, 1.03]
4 studies · 1701 participants
Low

Complete revascularisation vs culprit‐only revascularisation

Short‐term all‐cause mortality (within the first 30 days after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes short‐term all‐cause mortality (within the first 30 days after the… compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete versus culprit‐only revascularisation in ST elevation myocardial infarction with multi‐vessel disease 2017 · Cochrane Headline outcomes only
RR 0.65 [0.18, 2.37]
2 studies · 696 participants
Very low